The happy gist of Ziopharm Oncology Inc.'s interim Phase II news with palifosfamide for soft-tissue sarcoma came as little surprise, but details disclosed at a scientific meeting proved enough to tickle the stock again by 12 percent, and should lend strength to partnering talks. (BioWorld Today) Read More
